Compass Pathways' stock rose 4% following new 52-week data from its Phase III study of COMP360, an oral psilocybin treatment for treatment-resistant depression (TRD). The data showed sustained symptom improvement with infrequent dosing, supporting the drug's safety and efficacy. Analysts at Jefferies are confident in FDA approval, noting the drug's Breakthrough Therapy Designation and priority review status, with a potential launch in early 2027. COMP360's less frequent dosing offers a competitive advantage over existing treatments like Johnson & Johnson's Spravato, with estimated peak sales of $1.5 billion and a company valuation between $3 billion and $4.5 billion.
SailPoint reported Q2 2026 earnings with revenue of $308.81 million, slightly below estimates but up 17% year-over-year. Adjusted EPS of $0.09 beat analyst expectations by 12.5%, reflecting improved profitability. The company showed strong subscripti...
The Cooper Companies is set to report its Q3 2026 earnings with analysts expecting earnings per share (EPS) of $1.12 and revenue of $1.10 billion, both showing growth from the previous year. Despite a recent 2.7% drop in stock price to $67.69, an ana...
Intellia Therapeutics saw a boost after Wedbush analyst raised its price target to $13, signaling potential upside from its current $12.64 share price. The FDA granted Priority Review to Intellia's lonvo-z treatment for Hereditary Angioedema, with a ...
Signet Jewelers reported Q2 fiscal 2027 earnings of $2.19 per share, surpassing analyst estimates of $1.69 by nearly 30%, marking its sixth consecutive quarter of earnings beats. Although revenue slightly missed expectations at $1.528 billion versus ...
UBS increased its price target for ABM Industries to $51.50 following the company's strong quarterly earnings and revenue growth. ABM reported a 4.2% revenue increase to $2.32 billion and a 19% rise in net income to $49.7 million, alongside strong ca...
